Ally Financial Inc. bought a new position in Celgene Corporation (NASDAQ:CELG) during the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 20,000 shares of the biopharmaceutical company’s stock, valued at approximately $2,597,000.

Other institutional investors and hedge funds also recently modified their holdings of the company. Century Capital Management LLC boosted its position in Celgene by 12.7% during the first quarter. Century Capital Management LLC now owns 65,146 shares of the biopharmaceutical company’s stock worth $8,106,000 after purchasing an additional 7,335 shares in the last quarter. Airain ltd boosted its position in Celgene by 136.5% during the first quarter. Airain ltd now owns 137,429 shares of the biopharmaceutical company’s stock worth $17,100,000 after purchasing an additional 79,328 shares in the last quarter. Ingalls & Snyder LLC boosted its position in Celgene by 24.3% during the first quarter. Ingalls & Snyder LLC now owns 30,709 shares of the biopharmaceutical company’s stock worth $3,821,000 after purchasing an additional 6,003 shares in the last quarter. Northwestern Mutual Investment Management Company LLC boosted its position in Celgene by 76.7% during the first quarter. Northwestern Mutual Investment Management Company LLC now owns 157,260 shares of the biopharmaceutical company’s stock worth $19,568,000 after purchasing an additional 68,244 shares in the last quarter. Finally, BP PLC boosted its position in Celgene by 22.7% during the first quarter. BP PLC now owns 119,000 shares of the biopharmaceutical company’s stock worth $14,807,000 after purchasing an additional 22,000 shares in the last quarter. Hedge funds and other institutional investors own 80.17% of the company’s stock.

In related news, insider Terrie Curran sold 1,727 shares of the stock in a transaction that occurred on Monday, September 25th. The stock was sold at an average price of $143.89, for a total value of $248,498.03. Following the completion of the sale, the insider now owns 3,925 shares of the company’s stock, valued at $564,768.25. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, Director Michael D. Casey sold 9,250 shares of the stock in a transaction that occurred on Tuesday, September 5th. The shares were sold at an average price of $139.03, for a total value of $1,286,027.50. Following the completion of the sale, the director now directly owns 9,250 shares of the company’s stock, valued at approximately $1,286,027.50. The disclosure for this sale can be found here. In the last ninety days, insiders sold 20,227 shares of company stock valued at $2,843,956. Insiders own 0.95% of the company’s stock.

Celgene Corporation (NASDAQ CELG) opened at $103.12 on Thursday. The firm has a market capitalization of $81,873.09, a P/E ratio of 16.25, a PEG ratio of 0.80 and a beta of 1.79. Celgene Corporation has a 1 year low of $94.55 and a 1 year high of $147.17. The company has a debt-to-equity ratio of 1.31, a current ratio of 3.65 and a quick ratio of 3.52.

Celgene (NASDAQ:CELG) last posted its quarterly earnings results on Thursday, October 26th. The biopharmaceutical company reported $1.91 EPS for the quarter, beating the consensus estimate of $1.87 by $0.04. Celgene had a return on equity of 63.80% and a net margin of 27.36%. The firm had revenue of $3.29 billion during the quarter, compared to analysts’ expectations of $3.42 billion. During the same quarter last year, the firm earned $1.58 earnings per share. The business’s revenue for the quarter was up 10.2% on a year-over-year basis. sell-side analysts expect that Celgene Corporation will post 6.67 EPS for the current year.

A number of equities analysts have issued reports on the company. Morgan Stanley downgraded Celgene from an “equal weight” rating to an “underweight” rating and set a $120.00 price target on the stock. in a research report on Thursday, October 5th. Royal Bank Of Canada reiterated a “buy” rating and set a $173.00 price target on shares of Celgene in a research report on Thursday, October 5th. Robert W. Baird reiterated a “buy” rating and set a $162.00 price target on shares of Celgene in a research report on Thursday, September 21st. Cantor Fitzgerald reiterated a “buy” rating and set a $162.00 price target on shares of Celgene in a research report on Tuesday, September 26th. Finally, Jefferies Group reiterated a “buy” rating and set a $160.00 price target on shares of Celgene in a research report on Friday, September 15th. One equities research analyst has rated the stock with a sell rating, eleven have issued a hold rating, nineteen have given a buy rating and two have issued a strong buy rating to the stock. The stock currently has an average rating of “Buy” and a consensus target price of $139.57.

TRADEMARK VIOLATION WARNING: “Ally Financial Inc. Buys Shares of 20,000 Celgene Corporation (CELG)” was first published by Daily Political and is the property of of Daily Political. If you are accessing this article on another site, it was copied illegally and republished in violation of U.S. and international trademark and copyright law. The correct version of this article can be viewed at https://www.dailypolitical.com/2017/11/30/ally-financial-inc-buys-shares-of-20000-celgene-corporation-celg.html.

About Celgene

Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.

Institutional Ownership by Quarter for Celgene (NASDAQ:CELG)

Receive News & Ratings for Celgene Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene Corporation and related companies with MarketBeat.com's FREE daily email newsletter.